背景:心肌梗死（MI）是全世界內發(fā)病率和死亡率最高的疾病之一。心肌梗死通常是由于冠狀動脈在斑塊破裂或侵蝕的部位發(fā)生血栓導致血管閉塞所致。懷疑或確診為急性心肌缺血或梗死的患者可診斷為急性冠脈綜合征（ACS）。非ST段抬高型心肌梗死（NSTEMI）,不穩(wěn)定型心絞痛和ST段抬高型心肌梗死（STEMI）是ACS的三種類型。ST段抬高型心肌梗死（STEMI）是由心肌缺血的典型癥狀、持續(xù)性ST段抬高的心電圖改變（STE）以及其后繼發(fā)的心肌損傷標志物水平改變三者共同定義的臨床綜合征。在標準條件下進行診斷時,STEMI的診斷標準為心電圖表現(xiàn)為至少有兩個相鄰導聯(lián)ST段抬高≥1mm（0.1mV）以及心肌損傷標志物升高。心電圖（ECG）是針對心肌梗死患者的初步檢查,心肌損傷標志物的血液檢查可以證明患者患有心肌梗死。而超聲心動圖檢查（ECHO）由于可以進一步診斷心肌梗死的早期和晚期并發(fā)癥,從而被認為是對于所有急性心肌梗死患者而言具有診斷意義的診斷性檢查項目。超聲心動圖檢查是一種非侵入性的診斷技術,它可以提供有關心臟功能和血液動力學的信息并且對患有AMI機械并發(fā)癥的患者進行病情評估。AMI的主要機械并發(fā)癥分別是... 

【文章來源】：吉林大學吉林省 211工程院校 985工程院校 教育部直屬院校

【文章頁數(shù)】：87 頁

【學位級別】：碩士

【文章目錄】：
摘要
abstract
CHAPTER 1:INTRODUCTION
    1.1 BACKGROUND
    1.2 UNIVERSAL DEFINITION OF MYOCARDIAL INJURY AND MYOCARDIAL INFARCTION
    1.3 EPIDEMIOLOGY
    1.4 CLASSIFICATION
    1.5 RISK FACTORS
    1.6 PATHOGENESIS
    1.7 CLINICAL FEATURES
    1.8 INVESTIGATION
        1.8.1 Electrocardiography
        1.8.2 Cardiac Enzymes and Cardiac Markers
        1.8.3 Chest X-ray
        1.8.4 Echocardiography
        1.8.5 Coronary Angiography
    1.9 PROGNOSIS
    1.10 TREATMENT
        1.10.1 Prehospital care
        1.10.2 Emergency department and in-hospital management
        1.10.3 Routine measures in the treatment of STEMI
        1.10.4 Treatment in right ventricular infarction
    1.11 COMPLICATIONS
CHAPTER 2:LITERATURE REVIEW
    2.1 STRUCTURAL HEART DISEASE AS A COMPLICATION OF MYOCARDIAL INFARCTION
        2.1.1 Background
        2.1.2 Structural heart disease
    2.2 MECHANICAL COMPLICATION OF STEMI
        2.2.1 Mitral regurgitation（MR）:
        2.2.2 Tricuspid regurgitation（TR）
    2.3 AORTIC REGURGITATION
CHAPTER 3:METHODS AND MATERIALS
    3.1 OBJECTIVE OF STUDY
        3.1.1 Aim
        3.1.2 Objective
    3.2 STUDY DESIGN
    3.3 STUDY POPULATION
    3.4 METHOD
        3.4.1 Inclusion criteria
        3.4.2 Exclusion criteria
        3.4.3 Electrocardiography
        3.4.4 Echocardiography
        3.4.5 Division of patients
    3.5 STATISTICAL ANALYSIS
    3.6 STUDY LIMITATIONS
CHAPTER 4:RESULTS
    4.1 STUDY POPULATION
    4.2 BIOCHEMICAL PARAMETERS AND ECHOCARDIOGRAPHIC MEASUREMENT
    4.3 COMPARISON BETWEEN STRUCTURAL HEART DISEASE AND NON-STRUCTURAL HEART DISEASE
    4.4 COMPARISON BETWEEN PATIENTS WITH MITRAL REGURGITATION AND WITHOUT MITRAL REGURGITATION
    4.5 COMPARISON BETWEEN THE PATIENT WITH AORTIC REGURGITATION AND WITHOUT AORTIC REGURGITATION
    4.6 COMPARISON BETWEEN THE PATIENT WITH TRICUSPID REGURGITATION AND WITHOUT TRICUSPID REGURGITATION
    4.7 MAJOR ADVERSE CARDIOVASCULAR EVENTS（MACE）
CHAPTER 5:DISCUSSION
CHAPTER 6:CONCLUSION
REFERENCE
AUTHOR'S INTRODUCTION
ACKNOWLEDGEMENT



本文編號：3090694